Patents-Review.com
ClassID:

112254 ⎘

C12N2810/85 - CPC Classification

Classification description:

Vectors comprising a targeting moiety; Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian

Sub-classes:
Recent Application in this class:
#1
20240327478
2024-10-03

DELIVERY OF CAS9 VIA ARRDC1-MEDIATED MICROVESICLES (ARMMS)

 #2
20220127648
2022-04-28

GENETICALLY ENGINEERED YEAST YARROWIA LIPOLYTICA AND METHODS FOR PRODUCING BIO-BASED GLYCOLIC ACID

 #3
20210324044
2021-10-21

Heterologous targeting peptide grafted AAVs

 #4
20210261930
2021-08-26

Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)

 #5
20200148745
2020-05-14

Gene therapy vectors for treatment of Danon disease

 #6
20200102550
2020-04-02

TAL effector-mediated DNA modification

 #7
20190389934
2019-12-26

Heterologous targeting peptide grafted AAVS

 #8
20190241876
2019-08-08

Delivery of cargo proteins via ARRDC1-mediated microvesicles (ARMMs)

 #9
20190170742
2019-06-06

COMPOSITIONS, KITS AND METHODS FOR IN VITRO ANTIGEN PRESENTATION, ASSESSING VACCINE EFFICACY, AND ASSESSING IMMUNOTOXICITY OF BIOLOGICS AND DRUGS

 #10
20190119691
2019-04-25

Vectors for cloning and expression of proteins, methods and applications thereof

 #11
20180265571
2018-09-20

Heterologous targeting peptide grafted AAVS

 #12
20180256740
2018-09-13

METHODS AND COMPOSITIONS RELATED TO ADENOASSOCIATED VIRUS-PHAGE PARTICLES

 #13
20180119118
2018-05-03

Delivery of cargo proteins via ARRDC1-mediated microvesicles (ARMMs)

 #14
20180080046
2018-03-22

Viral vectors for the treatment of retinal dystrophy

 #15
20180066286
2018-03-08

NUCLEAR TARGETING SEQUENCES

 #16
20170128594
2017-05-11

Humanized viral vectors and methods of use thereof

 #17
20160222415
2016-08-04

Nuclear targeting sequences

 #18
20160206566
2016-07-21

Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)

 #19
20160102319
2016-04-14

CMP-ACETYLNEURAMINIC ACID HYDROXYLASE TARGETING VECTOR, TRANSGENIC ANIMAL FOR XENOTRANSPLANTATION INTRODUCED WITH THE VECTOR, AND METHOD OF MANUFACTURING THE SAME

 #20
20160097061
2016-04-07

Viral vectors for the treatment of retinal dystrophy

 #21
20160074448
2016-03-17

Herpes simplex virus (HSV) with modified tropism, uses and process of preparation thereof

 #22
20160024476
2016-01-28

Anti-mycobacterial vaccines

 #23
20150125393
2015-05-07

Liposome and method for producing liposome

 #24
20140335568
2014-11-13

Nucleic acid assembly, vector, cell, methods and kit thereof

 #25
20140329891
2014-11-06

In vitro and In vivo delivery of genes and proteins using the bacteriophage T4 DNA packaging machine

 #26
20140256796
2014-09-11

In vitro and in vivo delivery of genes and proteins using the bacteriophage T4 DNA packaging machine

 #27
20120220492
2012-08-30

Viral Vectors with Improved Properties

 #28
20120214228
2012-08-23

TAL effector-mediated DNA modification

 #29
20120178903
2012-07-12

Methods and compositions related to adenoassociated virus-phage particles

 #30
20120178169
2012-07-12

Tal effector-mediated DNA modification

 #31
20120178131
2012-07-12

TAL effector-mediated DNA modification

 #32
20120129199
2012-05-24

COMPOSITIONS, KITS AND METHODS FOR IN VITRO ANTIGEN PRESENTATION, ASSESSING VACCINE EFFICACY, AND ASSESSING IMMUNOTOXICITY OF BIOLOGICS AND DRUGS

 #33
20120020878
2012-01-26

FUSOGENIC PROPERTIES OF SAPOSIN C AND RELATED PROTEINS AND PEPTIDES FOR APPLICATION TO TRANSMEMBRANE DRUG DELIVERY SYSTEMS

 #34
20110318268
2011-12-29

Herpes simplex virus (HSV) with modified tropism, uses and process of preparation thereof

 #35
20110145940
2011-06-16

TAL effector-mediated DNA modification

 #36
20100278846
2010-11-04

NASAL-ADMINISTERED VACCINES USING MULTI-SCREENED NALT-TARGETING AND PHAGOCYTIC POLYPEPTIDE TRANSPORT SEQUENCES

 #37
20100254896
2010-10-07

Methods and compositions related to adenoassociated virus-phage particles

 #38
20100215582
2010-08-26

LIPOSOME AND METHOD FOR PRODUCING LIPOSOME

 #39
20100099627
2010-04-22

Nuclear targeting sequences

 #40
20100098666
2010-04-22

Humanized Viral Vectors and Methods of Use Thereof

 #41
20100093838
2010-04-15

Regulation of angiogenesis with zinc finger proteins

 #42
20100016413
2010-01-21

Pathotropic targeted gene delivery system for cancer and other disorders

 #43
20100003197
2010-01-07

Ultrasmall superparamagnetic iron oxide nanoparticles and uses thereof

 #44
20090215870
2009-08-27

Compositions and methods for targeting of viral vectors

 #45
20090191261
2009-07-30

Antibody fragment-targeted immunoliposomes for systemic gene delivery

 #46
20090074810
2009-03-19

Modified Adenovirus Hexon Protein and Uses Thereof

 #47
20080112929
2008-05-15

SHIELDED ADENOVIRAL VECTORS AND METHODS OF USE

 #48
20080071068
2008-03-20

Cytoplasmic Localization Dna and Rna

 #49
20080032341
2008-02-07

Method and kit for expressing protein under regulation of the expression from repeated sequence formed by gene amplification, and transformant

 #50
20080019988
2008-01-24

Targeting of genetic vaccine vectors

 #51
20070298458
2007-12-27

Method And Kit For Expressing Protein Under Regulation Of The Expression From Repeated Sequence Formed By Gene Amplification, And Transformant

 #52
20070281356
2007-12-06

Nuclear transport nucleic acid delivery vector

 #53
20070274908
2007-11-29

METHODS AND COMPOSITIONS RELATED TO ADENOASSOCIATED VIRUS-PHAGE PARTICLES

 #54
20070178066
2007-08-02

PATHOTROPIC TARGETED GENE DELIVERY SYSTEM FOR CANCER AND OTHER DISORDERS

 #55
20070072818
2007-03-29

Regulation of angiogenesis with zinc finger proteins

 #56
20070065432
2007-03-22

Antibody fragment-targeted immunoliposomes for systemic gene delivery

 #57
20060286545
2006-12-21

Viral vectors with improved properties

 #58
20050267062
2005-12-01

Regulation of angiogenesis with zinc finger proteins

 #59
20050260605
2005-11-24

Targeting of genetic vaccine vectors